The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
Orion to receive an upfront payment of USD 290 million
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
An algorithm based testing for Fatty Liver Disease
This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
The AICVD tool can predict the risk of cardiovascular disease.
Subscribe To Our Newsletter & Stay Updated